2511 — HighTide Therapeutics Cashflow Statement
0.000.00%
- HK$803.80m
- HK$364.54m
Annual cashflow statement for HighTide Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -221 | -190 | -939 | -382 |
Depreciation | ||||
Non-Cash Items | 116 | -8.21 | 592 | 73.7 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 13.3 | 24.8 | -11.6 | 3.41 |
Change in Prepaid Expenses | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Other Liabilities | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -90.5 | -172 | -357 | -298 |
Capital Expenditures | -1.75 | -0.183 | -0.801 | -4.29 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | 3.33 | -415 | 316 | -50.4 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | 1.59 | -416 | 315 | -54.7 |
Financing Cash Flow Items | -18.4 | -1.25 | 114 | -1.53 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 494 | 46 | 361 | 49 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 398 | -492 | 335 | -297 |